One or two doses of oxfendazole compared to two doses of triclabendazole for chronic fascioliasis
Official title: A Non-Inferiority Randomized Single Blind Controlled Trial Comparing One and Two Dose Regimes of Oxfendazole versus a Two Dose Regime of Triclabendazole to Treat Chronic Fascioliasis
Funded at Universidad Peruana Cayetano Heredia · NIH-11401344 · Data updated 2026-11-12
This study checks whether giving one or two doses of oxfendazole works as well as the standard two-dose triclabendazole to treat chronic fascioliasis in adults and older children.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Universidad Peruana Cayetano Heredia NIH-funded |
| Lab location | 1 site (Lima, Peru) |
| Project start | August 17, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $531,697 |
| NIH project number | 5U01AI155323-04 |
| Project ID | NIH-11401344 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults and children with chronic Fasciola hepatica infection in endemic regions, especially where drug access is limited.
✕Less likely to help
Patients with non-fascioliasis liver conditions or those intolerant to oxfendazole or triclabendazole may not benefit.
What this research studies
This trial compares different dosing regimens of three antiparasitic drugs to treat Fasciola hepatica infection. It is designed as a non-inferiority, randomized, single-blind study to see if one or two doses of oxfendazole can match the effectiveness of two doses of triclabendazole. Participants include individuals across a broad age range in endemic regions, with attention to symptoms like anemia and liver disease. The study will monitor clinical outcomes and safety to determine if a simpler, potentially more accessible oxfendazole regimen could be a viable alternative for patients. Results could influence treatment guidelines and drug availability for affected communities.
Why it matters
Potential benefit: If successful, patients could have a simpler, potentially more accessible treatment option for chronic fascioliasis.
How similar studies have gone: Previous trials have demonstrated efficacy of triclabendazole and ongoing research into alternative regimens; non-inferiority results could support broader use of oxfendazole.
Where this research is happening
-
Universidad Peruana Cayetano Heredia
Lima, Peru Active
Researchers
- Principal investigator: Garcia, Hector Hugo — Universidad Peruana Cayetano Heredia
- Study coordinator: Garcia, Hector Hugo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.